Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)2024 · 15 citations
2Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-AnalysesMeta-Analysis · 2012 · 30 citations
3Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA ( EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) studyCohort Study · 2021 · 21 citations
4Efficacy and Safety of Il-17 Inhibitors in Moderate-To-Severe Plaque Psoriasis: A Systematic Review and Meta-AnalysisMeta-Analysis · 2026
5Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern ItalyClinical Trial · 2026
6Systemic Pharmacological Treatments for Chronic Plaque PsoriasisOriginal Research · 2026 · 4 citations
7RETROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF INFLIXIMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS2025
8Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)Original Research · 2024 · 5 citations
9Real‐world effects of beremagene geperpavec in epidermolysis bullosaJournal of the European Academy of Dermatology and Venereology · 2026
10Michael Jackson, Vitiligo and the 2026 biopic: Global search interest and persistent misconceptionsJournal of the European Academy of Dermatology and Venereology · 2026

More from Journal of the European Academy of Dermatology and Venereology

More from Yale University